You're contacting media contact of this press release

Title: Premium Supplement NMN KIWAMI Made in Japan with FDA Compliance Seeks Strategic U.S. Distribution Partnerships

Japan, 3rd Mar 2026 - Asa Pharmaceutical Co., Ltd. (Headquarters: Minato Ward, Tokyo; President and CEO: Tomoko Iwase), a manufacturer and distributor of health supplements, announced that effective Monday, January 26, 2026, it will significantly strengthen its supply structure for the Japanese-made NMN supplement NMN KIWAMI in the North American market and will officially begin accepting applications for local sales distributors. NMN KIWAMI is sold exclusively through medical institutions in Japan due to its high quality and is also used as a raw material for NMN intravenous therapy, positioning it as a professional-use product. With a repeat purchase rate reaching 95%, NMN KIWAMI enters the rapidly expanding U.S. longevity market as a uniquely positioned supplement that combines advanced Japanese manufacturing standards with full compliance with U.S. regulatory requirements, aiming to expand market share in collaboration with strategic local partners.Four Reasons Why U.S. Distributors Should Choose NMN KIWAMI1. Exceptional Compliance and Safety (FDA & Informed Sport)Regulatory compliance represents the highest barrier in the U.S. supplement market. NMN KIWAMI uses domestically produced raw materials that meet FDA standards and has obtained Informed Sport certification, which complies with World Anti-Doping Agency (WADA) guidelines. This allows distributors serving professional athletes and celebrities to add the product to their portfolios with confidence. 2. Reliability Based on Clinical EvidenceHuman clinical trials involving subjects aged 50 to 61 demonstrated improvements in insulin resistance and triglyceride levels, as well as confirmed lengthening of telomeres, a key biomarker of aging. These data provide strong appeal to evidence-driven, high-inc...

This press release is issued by King Newswire